Transcript AC2993 (Synthetic Exendin-4) A Potential New Anti

Presenter Disclosure Information
In compliance with the accrediting board policies, the
American Diabetes Association requires the following
disclosure to the participants:
NAME OF PRESENTER:
Curtis Triplitt, PharmD, CDE
Speaker’s Bureau: Amylin, Eli Lilly, Novartis, Takeda
Board Member/Advisory Panel: Amylin, Eli Lilly
Treating Type 2 DM in the 21st
Century
Curtis Triplitt, PharmD, CDE
Texas Diabetes Institute
Asst. Professor, Dept. of Medicine/ Div. of Diabetes
Clinical Assistant Professor of Pharmacy
University of Texas Health Science Center
San Antonio, Texas
• Presentation not available due to pending
publication and intellectual property issues.
The following references were used:
• Pathophysiologic Basis of Treatment: Adapted from Inzucchi SE. JAMA. 2002;287:360-372
• Factors that Influence the Efficiency of Inhaled Insulin: Nature Reviews Drug Discovery 1; 529-540 (2002)
• Exubera Inhaled Insulin
Change-Baseline FEV1 in T1DM: September 8, 2005, EMDAC Meeting, Food and Drug Administration
• Exubera Inhaled Insulin
Change-Baseline DLCO in Type 1 DM - Pooled Phase 2 and 3 Studies: September 8, 2005, EMDAC Meeting, Food and Drug
Administration
• Technosphere/MannKind
Insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler: Diabetes Technology and Therapeutics
2002;4(5):589
• Technosphere/MannKind
Inhaled Insulin: Rosenstock J.et al. ADA Scientific Sessions. 2005, San Diego, CA: 357-OR
• When Does Beta-Cell Function Decline? Ferrannini, E. et al. J Clin Endocrinol Metab 2005;90:493-500
• Initial Combination Therapy With
Sitagliptin Plus Metformin Study: Design-Data available on request from Merck & Co., Inc. Please specify 20752930(1)-JAN.
• Initial Combination Therapy With Sitagliptin Plus Metformin Study:
A1C Results Through 104 Wks (2 years): 1. Goldstein BJ et al. Diabetes Care. 2007;30(8):1979–1987. 2. Data available on
request from Merck & Co., Inc. Please specify 20752930(1)-JAN.
• Study Results: Placebo-subtracted HbA1c Reductions in Combination Therapy Studies- Williams-Herman D, et al. Abstract
875. Presented at the 19th World Diabetes Congress, 3–7 December 2006, Cape Town, South Africa.
• Liraglutide’s Impact on Glucagon Secretion inType 2 Diabetes Mellitus- Degn KB, et al. Diabetes 2004, 53:1187-1194
• Exenatide BID versus Exenatide QW- Drucker D, Buse JB, Taylor K et al. DURATION-1 trial online Lancet Sept 8 2008
DOI:10.1016/S0140-6736(08)61206-4
• A1C: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss
over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco,CA.
• FPG: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss
over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA.
• Weight Loss Through Week 52-Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52
weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA.
• Type 2 DM: Pancreatitis-1. Frey et al. Pancreas 2006. 33(4): 336-344.2. Martinez et al. Pancreatology 2006;6:206-209
• Liraglutide and Calcitonin-http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf
• Thiazolidinediones- Nature Medicine 2005;11:861-866
• Limb Fractures in Women with Rosiglitazone- J of Endocrinology 2004;183:203-16; Nature Medicine 2007;13:1496-1503